Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.

ABSTRACT: Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis-dependent CKD, and for iron deficiency anemia (IDA) in non-dialysis CKD. Elevated Pi and IDA both lead to increased FGF23, however, the roles of iron and FGF23 during CKD remain unclear. To this end, iron and Pi metabolism were tested in a mouse model of CKD (0.2% adenine) ± 0.5% FC for 6 weeks, with and without osteocyte deletion of Fgf23 (flox-Fgf23/Dmp1-Cre). Intact FGF23 (iFGF23) increased in all CKD mice but was lower in Cre⁺ mice with or without FC, thus the Dmp1-Cre effectively reduced FGF23. Cre⁺ mice fed AD-only had higher serum Pi than Cre^- pre- and post-diet, and the Cre⁺ mice had higher BUN regardless of FC trea

SUBMITTER: Liesen MP 

PROVIDER: S-EPMC9163801 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature